BPTH Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 16:00):

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States...

Stats
Today's Volume	82.91M
Average Volume	39 855.00
Market Cap	3.17M
EPS	$0 ( 2024-03-29 )
Next earnings date	( $-4.54 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.120
ATR14	$0.113 (2.72%)

Insider Trading

Date	Person	Action	Amount	type
2023-05-02	Cleaver Heath	Buy	10 000	Common Stock Option (right to buy)
2023-05-02	Aubert Paul	Buy	10 000	Common Stock Option (right to buy)
2023-05-02	Sherwood Aline	Buy	10 000	Common Stock Option (right to buy)
2023-05-02	Morris Douglas P	Buy	13 000	Common Stock Option (right to buy)
2023-05-02	Nielsen Peter Henry	Buy	105 000	Common Stock Option (right to buy)

INSIDER POWER
100.00
Last 88 transactions
Buy: 10 429 808 \| Sell: 661 335

Volume Correlation

Long: 0.45 (neutral)

Short: 0.62 (weak)

Signal:(60.197) Neutral

Bio Path Holdings Inc Correlation

10 Most Positive Correlations
BDTX	0.897
PXLW	0.89
IMAB	0.88
SHYF	0.879
FULC	0.876
CPIX	0.874
RMRM	0.873
IVA	0.872
QMCO	0.871
DADA	0.87

10 Most Negative Correlations
LEDS	-0.893
PPBT	-0.881
CINC	-0.87
ASUR	-0.86
SNCR	-0.857
SLGG	-0.851
TSLA	-0.835
MTEK	-0.834
RIBT	-0.827
XOG	-0.823

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Bio Path Holdings Inc Correlation - Currency/Commodity

0.37
( neutral )

-0.08
( neutral )

0.00
( neutral )

0.47
( neutral )

0.35
( neutral )

-0.55
( weak negative )

Bio Path Holdings Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-178 000 (0.00 %)
EPS:	$-33.64

Q4	2023
Revenue:	$0
Gross Profit:	$-41 000.00 (0.00 %)
EPS:	$-5.46

Q3	2023
Revenue:	$0
Gross Profit:	$-46 000.00 (0.00 %)
EPS:	$-6.36

Q2	2023
Revenue:	$0
Gross Profit:	$-46 000.00 (0.00 %)
EPS:	$-10.64

Financial Reports:

No articles found.

Bio Path Holdings Inc

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.